Cargando…

Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance

BACKGROUND: Mortality rates for patients with Staphylococcus aureus (S. aureus) infections have improved only modestly in recent decades and S. aureus infections remain a major clinical challenge This study investigated the in vitro antimicrobial activity of erevacycline (erava) against clinical S....

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Fan, Bai, Bing, Xu, Guang-jian, Lin, Zhi-wei, Li, Gui-qiu, Chen, Zhong, Cheng, Hang, Sun, Xiang, Wang, Hong-yan, Chen, Yan-wei, Zheng, Jin-xin, Deng, Qi-wen, Yu, Zhi-jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293590/ https://www.ncbi.nlm.nih.gov/pubmed/30545293 http://dx.doi.org/10.1186/s12866-018-1349-7

Ejemplares similares

Overexpression of OqxAB and MacAB efflux pumps contributes to eravacycline resistance and heteroresistance in clinical isolates of Klebsiella pneumoniae
por: Zheng, Jin-xin, et al.
Publicado: (2018)

In Vitro Activity of the Novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, Against Moraxella catarrhalis
por: Sun, Xiang, et al.
Publicado: (2021)

Omadacycline Efficacy against Enterococcus faecalis Isolated in China: In Vitro Activity, Heteroresistance, and Resistance Mechanisms
por: Lin, Zhiwei, et al.
Publicado: (2020)

Omadacycline, Eravacycline, and Tigecycline Express Anti-Mycobacterium abscessus Activity In Vitro
por: Li, Anqi, et al.
Publicado: (2023)

In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates
por: Zeng, Weiliang, et al.
Publicado: (2022)

Mechanism of Eravacycline Resistance in Clinical Enterococcus faecalis Isolates From China
por: Wen, Zewen, et al.
Publicado: (2020)

In vitro activity of eravacycline against common ribotypes of Clostridioides difficile
por: Bassères, Eugénie, et al.
Publicado: (2020)

In Vitro Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria
por: Zhang, Tingting, et al.
Publicado: (2022)

Vancomycin Heteroresistance in Methicillin-resistant Staphylococcus aureus, Taiwan
por: Wang, Jiun-Ling, et al.
Publicado: (2004)

Molecular epidemiology of heteroresistant vancomycin-intermediate Staphylococcus aureus in Brazil
por: Silveira, Alessandro Conrado de Oliveira, et al.
Publicado: (2015)

In vitro Activity and Heteroresistance of Omadacycline Against Clinical Staphylococcus aureus Isolates From China Reveal the Impact of Omadacycline Susceptibility by Branched-Chain Amino Acid Transport System II Carrier Protein, Na/Pi Cotransporter Family Protein, and Fibronectin-Binding Protein
por: Bai, Bing, et al.
Publicado: (2019)

In Vitro Activity of Eravacycline and Comparator Antimicrobials Against 143 Strains of Bacteroides Species.
por: Citron, Diane, et al.
Publicado: (2017)

Antibacterial Activity of Eravacycline Against Carbapenem-Resistant Gram-Negative Isolates in China: An in vitro Study
por: Zou, Xuehan, et al.
Publicado: (2023)

Phenotypic Detection of Hemin-Inducible Trimethoprim-Sulfamethoxazole Heteroresistance in Staphylococcus aureus
por: Nurjadi, Dennis, et al.
Publicado: (2021)

Heteroresistance to Amikacin in Carbapenem-Resistant Klebsiella pneumoniae Strains
por: Zhang, Feiyang, et al.
Publicado: (2021)

Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies
por: Xu, Congjuan, et al.
Publicado: (2022)

In vitro activity of eravacycline and comparator agents against bacterial pathogens isolated from patients with cancer
por: Rolston, Kenneth, et al.
Publicado: (2023)

1259. Activity of eravacycline against staphylococci isolated from periprosthetic joint infections
por: Zhuchenko, Georg, et al.
Publicado: (2020)

Serotyping, MLST, and Core Genome MLST Analysis of Salmonella enterica From Different Sources in China During 2004–2019
por: Yan, Shigan, et al.
Publicado: (2021)

Changing Italian nosocomial-community trends and heteroresistance in Staphylococcus aureus from bacteremia and endocarditis
por: Campanile, F., et al.
Publicado: (2011)

In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland
por: Brauncajs, Małgorzata, et al.
Publicado: (2023)

In Vitro Activities of Aztreonam-Avibactam, Eravacycline, Cefoselis, and Other Comparators against Clinical Enterobacterales Isolates: a Multicenter Study in China, 2019
por: Chen, Jiawei, et al.
Publicado: (2023)

Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects
por: Newman, Joseph V., et al.
Publicado: (2019)

Genetic polymorphisms identify in species/biovars of Brucella isolated in China between 1953 and 2013 by MLST
por: Piao, Dong-ri, et al.
Publicado: (2018)

1243. Eravacycline in Bacteremia: A Case Series
por: Andrade, Justin A, et al.
Publicado: (2021)

Antibiotic Heteroresistance in Klebsiella pneumoniae
por: Stojowska-Swędrzyńska, Karolina, et al.
Publicado: (2021)

253 Activity of Eravacycline Against Enterobacteriaceae and Acinetobacter baumannii from New York City
por: Abdallah, Marie, et al.
Publicado: (2014)

Eravacycline susceptibility was impacted by genetic mutation of 30S ribosome subunits, and branched-chain amino acid transport system II carrier protein, Na/Pi cotransporter family protein in Staphylococcus aureus
por: Wang, Zhanwen, et al.
Publicado: (2020)

Molecular epidemiology of Staphylococcus aureus bacteremia in a single large Minnesota medical center in 2015 as assessed using MLST, core genome MLST and spa typing
por: Park, Kyung-Hwa, et al.
Publicado: (2017)

In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017
por: Morrissey, Ian, et al.
Publicado: (2020)

In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017
por: Morrissey, Ian, et al.
Publicado: (2020)

710. In Vitro Activity and Performance of Available Susceptibility Testing Methods for Eravacycline Against Carbapenem-Resistant Enterobacteriaceae (CRE)
por: Jones, Chelsea E, et al.
Publicado: (2019)

MentaLiST – A fast MLST caller for large MLST schemes
por: Feijao, Pedro, et al.
Publicado: (2018)

An Improved MLVF Method and Its Comparison with Traditional MLVF, spa Typing, MLST/SCCmec and PFGE for the Typing of Methicillin-Resistant Staphylococcus aureus
por: Du, Xue-Fei, et al.
Publicado: (2014)

Hinokitiol Selectively Enhances the Antibacterial Activity of Tetracyclines against Staphylococcus aureus
por: Le, Chun-Yan, et al.
Publicado: (2023)

Evidence from an In Vitro Study: Is Oxacillin Plus Vancomycin a Better Choice for Heteroresistant Vancomycin-Intermediate Staphylococcus aureus?
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2018)

Efflux Pump Overexpression Contributes to Tigecycline Heteroresistance in Salmonella enterica serovar Typhimurium
por: Chen, Yi, et al.
Publicado: (2017)

MLVA and MLST typing of Brucella from Qinghai, China
por: Ma, Jun-Ying, et al.
Publicado: (2016)

Quorum sensing regulates heteroresistance in Pseudomonas aeruginosa
por: Lu, Yang, et al.
Publicado: (2022)

Eravacycline: A Review in Complicated Intra-Abdominal Infections
por: Scott, Lesley J.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pc572b2lpe07jl2armpjfrb8jb